Literature DB >> 11292783

Contribution of CD8(+) T cells to gamma interferon production in human tuberculosis.

H Shams1, B Wizel, S E Weis, B Samten, P F Barnes.   

Abstract

The proportions of peripheral blood mononuclear cells (PBMC), CD4(+) T cells, and CD8(+) T cells that produce gamma interferon (IFN-gamma) in response to Mycobacterium tuberculosis were markedly reduced in tuberculosis patients, particularly in those with severe disease. Depletion of CD4(+) but not CD8(+) cells prior to stimulation of PBMC with M. tuberculosis abolished IFN-gamma production. These results show that (i) IFN-gamma production by CD8(+) and CD4(+) cells correlates with the clinical manifestations of M. tuberculosis infection and (ii) IFN-gamma production by CD8(+) cells depends on CD4(+) cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11292783      PMCID: PMC98319          DOI: 10.1128/IAI.69.5.3497-3501.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  Stimulation of human peripheral blood mononuclear cells with live Mycobacterium bovis BCG activates cytolytic CD8+ T cells in vitro.

Authors:  J Turner; H M Dockrell
Journal:  Immunology       Date:  1996-03       Impact factor: 7.397

2.  Dichotomy of cytokine profiles in patients and high-risk healthy subjects exposed to tuberculosis.

Authors:  S Bhattacharyya; R Singla; A B Dey; H K Prasad
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

3.  CD8+ CTL from lungs of Mycobacterium tuberculosis-infected mice express perforin in vivo and lyse infected macrophages.

Authors:  N V Serbina; C C Liu; C A Scanga; J L Flynn
Journal:  J Immunol       Date:  2000-07-01       Impact factor: 5.422

4.  Relative contributions of distinct MHC class I-dependent cell populations in protection to tuberculosis infection in mice.

Authors:  A O Sousa; R J Mazzaccaro; R G Russell; F K Lee; O C Turner; S Hong; L Van Kaer; B R Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

5.  Immune responsiveness and lymphokine production in patients with tuberculosis and healthy controls.

Authors:  F O Sánchez; J I Rodríguez; G Agudelo; L F García
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

6.  Th1/Th2 profiles in tuberculosis, based on the proliferation and cytokine response of blood lymphocytes to mycobacterial antigens.

Authors:  H M Surcel; M Troye-Blomberg; S Paulie; G Andersson; C Moreno; G Pasvol; J Ivanyi
Journal:  Immunology       Date:  1994-02       Impact factor: 7.397

7.  T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infection.

Authors:  M Zhang; J Gong; D V Iyer; B E Jones; R L Modlin; P F Barnes
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

8.  T-cell cytokine responses in human infection with Mycobacterium tuberculosis.

Authors:  M Zhang; Y Lin; D V Iyer; J Gong; J S Abrams; P F Barnes
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

9.  Characterization of human Mycobacterium bovis bacille Calmette-Guérin-reactive CD8+ T cells.

Authors:  S M Smith; A S Malin; T Pauline; S E Atkinson; J Content; K Huygen; H M Dockrell
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

10.  Helper activity is required for the in vivo generation of cytotoxic T lymphocytes.

Authors:  J A Keene; J Forman
Journal:  J Exp Med       Date:  1982-03-01       Impact factor: 14.307

View more
  11 in total

1.  Mycobacterium tuberculosis growth control by lung macrophages and CD8 cells from patient contacts.

Authors:  Claudia Carranza; Esmeralda Juárez; Martha Torres; Jerrold J Ellner; Eduardo Sada; Stephan K Schwander
Journal:  Am J Respir Crit Care Med       Date:  2005-10-06       Impact factor: 21.405

2.  Rhodococcus equi-specific cytotoxic T lymphocytes in immune horses and development in asymptomatic foals.

Authors:  Kristin M Patton; Travis C McGuire; Melissa T Hines; Robert H Mealey; Stephen A Hines
Journal:  Infect Immun       Date:  2005-04       Impact factor: 3.441

Review 3.  Vaccines for tuberculosis: novel concepts and recent progress.

Authors:  T Mark Doherty; Peter Andersen
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

Review 4.  Mycobacterium tuberculosis-specific CD8+ T cells and their role in immunity.

Authors:  Joshua S M Woodworth; Samuel M Behar
Journal:  Crit Rev Immunol       Date:  2006       Impact factor: 2.214

5.  Photodynamic therapy with recombinant adenovirus AdmIL-12 enhances anti-tumour therapy efficacy in human papillomavirus 16 (E6/E7) infected tumour model.

Authors:  Eun Kyung Park; Su-Mi Bae; Sun-Young Kwak; Sung Jong Lee; Yong-Wook Kim; Chan-Hee Han; Hyun-Jung Cho; Kyung Tae Kim; Young-Jae Kim; Hyun-Jung Kim; Woong Shick Ahn
Journal:  Immunology       Date:  2008-04-04       Impact factor: 7.397

6.  Serial interferon-gamma release assays after chemoprophylaxis in a tuberculosis outbreak cohort.

Authors:  S W Lee; S H Lee; J-J Yim
Journal:  Infection       Date:  2012-05-15       Impact factor: 3.553

Review 7.  T cell-mediated host immune defenses in the lung.

Authors:  Kong Chen; Jay K Kolls
Journal:  Annu Rev Immunol       Date:  2013       Impact factor: 28.527

Review 8.  Immunological mechanisms by which concomitant helminth infections predispose to the development of human tuberculosis.

Authors:  Patricia Méndez-Samperio
Journal:  Korean J Parasitol       Date:  2012-11-26       Impact factor: 1.341

9.  Clonal expansions of CD8+ T cells with IL-10 secreting capacity occur during chronic Mycobacterium tuberculosis infection.

Authors:  Joshua C Cyktor; Bridget Carruthers; Gillian L Beamer; Joanne Turner
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

10.  Mannose-capped lipoarabinomannan- and prostaglandin E2-dependent expansion of regulatory T cells in human Mycobacterium tuberculosis infection.

Authors:  Ankita Garg; Peter F Barnes; Sugata Roy; María F Quiroga; Shiping Wu; Verónica E García; Stephan R Krutzik; Steven E Weis; Ramakrishna Vankayalapati
Journal:  Eur J Immunol       Date:  2008-02       Impact factor: 6.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.